Kiromic BioPharma, Inc. (KRBP)
Market Cap | 399.93K |
Revenue (ttm) | n/a |
Net Income (ttm) | -35.41M |
Shares Out | 1.18M |
EPS (ttm) | -55.58 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 10,722 |
Open | 0.403 |
Previous Close | 0.385 |
Day's Range | 0.290 - 0.415 |
52-Week Range | 0.290 - 15.300 |
Beta | 0.16 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 13, 2023 |
About KRBP
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and... [Read more]
Financial Performance
Financial StatementsNews

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial in...

Kiromic BioPharma Welcomes Two New Directors to its Board
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artific...

Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer.

Kiromic BioPharma Submits Investigational New Drug Application for Phase 1 Trial with Deltacel for Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...

Kiromic BioPharma Announces Reverse Stock Split
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...

Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc.

Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...

Kiromic BioPharma CEO Issues Letter to Stockholders
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...

SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and Directors Under Investigation for Possible False Statements About Its Commercial Prospects
SAN FRANCISCO , Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating to...

Kiromic BioPharma Arranges Up to $10 Million Financing
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® artifici...

Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully-integrated biotherapeutics company using its proprietary DIAMOND® ...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Kiromic BioPharma (KRBP) Investors with Losses to Lead Plaintiff Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - October 4, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now.Relevant Per...

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 4, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPhar...

KRBP ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 4, 2022 in the Class Action Filed on Behalf of Kiromic BioPharma, Inc. Shareholders
NEW YORK , Oct. 4, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Kiromic BioPharma, Inc. (NASDAQ: KRBP) alleging that the ...

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. With Losses of $75,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 3, 2022 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Ki...

KRBP LAWSUIT ALERT: Levi & Korsinsky Notifies Kiromic BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
New York, New York--(Newsfile Corp. - October 3, 2022) - Levi & Korsinsky, LLP notifies investors in Kiromic BioPharma, Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP) of a class action securities la...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kiromic BioPharma Inc. -KRBP
NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Kiromic BioPharma Inc. ("Kiromic" or the "Company") (NASDAQ: KRBP). Such investors are advised ...

KRBP FINAL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP
New York, New York--(Newsfile Corp. - October 3, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - October 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPhar...

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Kiromic Investors of a Lead Plaintiff Deadline of October 4, 2022
NEW YORK , Oct. 3, 2022 /PRNewswire/ -- Attention Kiromic BioPharma, Inc. ("Kiromic") (NASDAQ: KRBP) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on...

KRBP Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, Pa. , Oct. 2, 2022 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Kiromic Bio...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Kiromic BioPharma (KRBP) Investors with Significant Losses to Contact Firm's Attorneys Before Oct. 4th Application Deadline in Securities Class Action
San Francisco, California--(Newsfile Corp. - October 1, 2022) - Hagens Berman urges Kiromic BioPharma, Inc. (NASDAQ: KRBP) investors who purchased Kiromic shares to submit your losses now. Class Perio...

KRBP TUESDAY DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP
NEW YORK , Sept. 30, 2022 /PRNewswire/ -- WHY:Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kiromic BioPharma, Inc. (NASDAQ: KRBP): (i) pursuant and/or tra...

KRBP DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Kiromic BioPharma, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm
Radnor, Pennsylvania--(Newsfile Corp. - September 30, 2022) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed ...

TUESDAY DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - September 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioP...